# Racial Disparities in Surgical Treatment of Obstructive Sleep Apnea

Samuel M. Cohen, MD, PhD<sup>1</sup>\*, Javier J.M. Howard, MD, MPH<sup>1</sup>\*, Michael C. Jin<sup>1</sup>\*, Jason Qian, MD<sup>1</sup>, and Robson Capasso, MD<sup>1</sup>

# Abstract

*Objective.* Determine risk factors for failure to receive surgical treatment among patients with obstructive sleep apnea.

Study Design. Population-based observational longitudinal cohort study.

Setting. Population-based database.

*Methods*. Multivariate analysis of 500,792 individuals with obstructive sleep apnea from Optum's deidentified Clinformatics Data Mart database (2004-2018).

Results. Black race, increased age, diabetes, atrial fibrillation, obesity, and congestive heart failure were independently associated with a decreased rate of surgery for obstructive sleep apnea. Asian race, hypertension, arrhythmias other than atrial fibrillation, pulmonary disease, and liver disease were independently associated with an increased rate of surgery for obstructive sleep apnea.

*Conclusion.* Racial disparities in health outcomes related to health care access and in economic resources have an enormous impact on public health and social equity. We found differences in rates of surgery for obstructive sleep apnea based on race. These data are consistent with others demonstrating disparities in medical treatment of sleep apnea with positive pressure and underline a need for a change in awareness and treatment in these populations.

## Keywords

obstructive sleep apnea, sleep apnea surgery, health disparities

Received February 3, 2022; accepted March 1, 2022.

R acial and ethnic disparities in health were brought recently to the forefront of public consciousness due to the disproportionate toll that the COVID-19 pandemic has taken on African American individuals<sup>1,2</sup> and the Black Lives Matter movement. However, these disparities are deep rooted in American society, originating from extensive social and structural inequities. Over hundreds of years, racism and discrimination have resulted in vast economic and



OTO Open 2022, Vol. 6(1) 1–7 © The Authors 2022 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/2473974X221088870 http://oto-open.org

educational disadvantages for African American individuals that result in decreased health care access and quality, ultimately leading to poorer health outcomes. We are now beginning to understand the scope of the issue.

Obstructive sleep apnea (OSA) is an enormous public health challenge that disproportionately affects African American individuals. Moderate to severe OSA (apnea-hypopnea index  $\geq$ 15) affects approximately 10% of US adults and is strongly associated with increased cardiovascular disease, diabetes, neurocognitive disease, and death. These health consequences are mitigated or prevented with treatment<sup>3</sup>; however, an alarming 80% to 90% of those who have OSA remain undiagnosed.<sup>4</sup>

Disturbingly, African American adults and children have a higher prevalence of OSA<sup>5-12</sup> and a decreased rate of treatment as compared with White people.<sup>13-20</sup> A recent study demonstrated moderate or severe OSA in 24% of African American adults, while just 5% of those had a prior diagnosis.<sup>21</sup> It is well known that the path to diagnosis and treatment for OSA can be tedious and fraught with opportunities to fall through the cracks, and African American patients are especially susceptible. One study found that only 38% of African American patients referred by their primary care providers eventually received an evaluation by a sleep clinician; 91% of those evaluated were diagnosed with OSA.<sup>22</sup> African American patients self-refer for sleep-disordered breathing at lower rates vs White patients<sup>23</sup> and have increased OSA severity at diagnosis.<sup>24</sup> Treatment does indeed reduce mortality among African American patients with OSA.<sup>19</sup> However, once a diagnosis has been made, data show decreased continuous positive airway pressure (CPAP) usage among African American individuals<sup>13-19</sup> (although others found no difference<sup>23,25</sup>).

There is no organic, scientifically valid explanation for these disparities across race. In contrast, socioeconomic

<sup>1</sup>Department of Otolaryngology–Head and Neck Surgery, School of Medicine, Stanford University, Stanford, California, USA <sup>\*</sup>These authors contributed equally to this article.

#### Corresponding Author:

Samuel M. Cohen, MD, PhD, Department of Otolaryngology–Head and Neck Surgery, Stanford University School of Medicine, 801 Welch Rd, Palo Alto, CA 94304, USA.

Email: smcohen@stanford.edu.

This Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution. NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). factors account for many disparities. It has been proposed, with limited data, that the increased prevalence of OSA among African American adults vs White adults can be explained by a higher rate of obesity.<sup>6,7,26,27</sup> The cause of the latter trend, though, is clear. Abundant data demonstrate that these increased rates of obesity are explained by socioeconomic factors, such as decreased access to affordable and healthy dietary options, access to health care, vocation, and walkability of neighborhoods.<sup>28-31</sup> While data exist showing disparities in diagnosis and treatment of OSA, to date there are limited data on demographic variables or comorbidities affecting rates of surgical treatment for OSA.

## Methods

This study was approved by the Stanford Institutional Review Board (IRB-40974).

## Data Source

All data were sourced from Optum's Clinformatics Data Mart administrative claims database, which contains the longitudinal health care records of commercially insured enrollees covered by qualifying health care plans from a health care insurance provider. Diagnoses can be queried through *ICD-9/ 10* codes (*International Classification of Disease*, *Ninth* and *Tenth Revision*), while procedures were inferred from Current Procedural Terminology (CPT) codes. As this data source parsed race/ethnicity as White, Black, Asian, and Hispanic, we refer to Black race rather than African American individuals for the remainder of this article. We acknowledge that White, Black, and Asian are races, while Hispanic vs non-Hispanic refers to ethnicity; we nevertheless present the variables set by our database.

## Cohort Identification

Adult patients (>18 years) with OSA were identified from Optum's Clinformatics Data Mart database (2014-2018), which is derived from a database of deidentified administrative health claims for members of large commercial and Medicare Advantage health plans.

Criteria for inclusion were initiation of CPAP therapy with either a formal diagnosis code corresponding to apnea or a polysomnogram within 1 month of CPAP initiation (Figure I). Development of this search strategy was required given the previously discovered low sensitivity of using only diagnosis codes for OSA for case identification.<sup>32</sup> The index diagnosis date was defined by the first OSArelated encounter (the first occurrence of CPAP initiation, polysomnogram within 1 month of CPAP initiation, or an apnea diagnosis within 1 month of CPAP initiation). Additionally, patients were required to have at least 1 year of continuous preindex follow-up. Comorbidities were defined per the Charlson Comorbidity Index. Additional comorbidities included hypertension, atrial fibrillation, increased body mass, and other cardiac arrhythmias. The primary outcome of interest was time to surgical intervention following OSA diagnosis. Eligible procedures were uvulopalatopharyngoplasty, septoplasty, tonsillectomy, turbinate reduction,

Inclusion Criteria
PSG ordered
and
CPAP prescribed within -1 months of PSG to end of follow-up
or
ICD-9/10 of OSA or unspecified sleep apnea and
CPAP that is prescribed within -1 months of sleep apnea diagnosis to end of follow-up
and
at least <u>1 year</u> continuous pre-index follow-up required, where the date of OSA diagnosis is defined as the first date of the PSG, CPAP, and OSA diagnosis dates
DCC nelvermererer CDAD continuous positive sinusu pressures OCA

obstructive sleep apnea

Figure 1. Inclusion criteria. Algorithm for inclusion of patients with OSA through available administrative data; adapted from McIsaac et al.  $^{32}$ 

hyoid myotomy, and genioglossus advancement. Maxillofacial surgery was not included. Other features in our analysis were demographic (age, sex, and race) and socioeconomic (income, education, and number of dependents in the household). An overall 500,792 patients were included in analysis, with demographic data for this cohort presented in **Table 1**.

## Statistical Analyses

Broadly, nonparametric approaches were used for 2-sample comparisons of continuous and categorical variables (Mann-Whitney U test and chi-square test of independence, respectively). A time-varying multivariable Cox regression approach, including all demographic and medical covariates (**Tables 2** and **3**), was used to interrogate the primary outcome of interest (presence of surgical treatment for OSA). Comorbidities were analyzed either as static variables or with time-varying analysis. Whereas static variables are associated with a patient only if they have been entered in the patient's chart at the time of initial OSA diagnosis, time-varying analysis incorporates any new diagnosis during the time between OSA diagnosis and the endpoint (surgery).

Time-varying covariates were selected a priori and included diabetes mellitus (with or without chronic complications), myocardial infarction, cerebrovascular disease, hypertension, atrial fibrillation, and other arrhythmias. Particularly over an extended period of follow-up, timevarying models can account for changes in a patient's current condition and their effects on the outcome of interest (in this case, undergoing surgery for OSA relief). Medical treatment of OSA has been shown to reduce morbidity and mortality and/or improve biomarkers associated with these conditions; thus, a new diagnosis of OSA may indicate a need for earlier surgery.<sup>33-38</sup> We limited the time-varying feature set to avoid increasing model complexity, which limits the model's applicability to new data by overfitting on the existing data. The time interval for the analysis began at the date that patients met inclusion criteria. These patients were followed until a surgical intervention for OSA or for as long as data

#### Table 1. Demographics.<sup>a</sup>

Age, y <sup>b</sup> 54.6     13.6       Sex     Male     313,801     62.7       Female     186,991     37.3       Race/ethnicity     Asian     12,140     2.4       Black     50,393     10.1       Hispanic     46,753     9.3       White     391,506     78.2       Income, \$         <50,000     108,560     21.7       50,000-100,000     153,534     30.7       > 100,000     156,226     31.2       Unknown     82,472     16.5       Education         High school diploma or less     136,065     27.2       Some college or associate degree     282,165     56.3       Bachelor degree or higher     82,562     16.5       Weight     11,283     2.3       Obese or morbidly obese     114,326     22.8       Comorbidites (at siagnosis)     114,326     22.8       Hypertension     288,611     57.6       Atrial fibrillation     35,353     7.1 <		No.	%
Sex     Male     313,801     62.7       Female     186,991     37.3       Race/ethnicity     Asian     12,140     2.4       Black     50,393     10.1       Hispanic     46,753     9.3       White     391,506     78.2       Income, \$         <50,000	Age, y <sup>b</sup>	54.6	13.6
Male     313,801     62.7       Female     186,991     37.3       Race/ethnicity     Asian     12,140     2.4       Black     50,393     10.1       Hispanic     46,753     9.3       White     391,506     78.2       Income, \$     -<50,000	Sex		
Female     186,991     37.3       Race/ethnicity     Asian     12,140     2.4       Black     50,393     10.1       Hispanic     46,753     9.3       White     391,506     78.2       Income, \$         <50,000	Male	3 3,80	62.7
Race/ethnicity     Asian     12,140     2.4       Black     50,393     10.1       Hispanic     46,753     9.3       White     391,506     78.2       Income, \$         <50,000	Female	186,991	37.3
Asian     12,140     2.4       Black     50,393     10.1       Hispanic     46,753     9.3       White     391,506     78.2       Income, \$         <50,000	Race/ethnicity		
Black     50,393     10.1       Hispanic     46,753     9.3       White     391,506     78.2       Income, \$         <50,000	Asian	12,140	2.4
Hispanic     46,753     9.3       White     391,506     78.2       Income, \$        <50,000	Black	50,393	10.1
White     391,506     78.2       Income, \$        <50,000	Hispanic	46,753	9.3
Income, \$     <50,000	White	391,506	78.2
<50,000	Income, \$		
50,000-100,000   153,534   30.7     >100,000   156,226   31.2     Unknown   82,472   16.5     Education	<50,000	108,560	21.7
>100,000   156,226   31.2     Unknown   82,472   16.5     Education	50,000-100,000	153,534	30.7
Unknown     82,472     16.5       Education     High school diploma or less     136,065     27.2       Some college or associate degree     282,165     56.3       Bachelor degree or higher     82,562     16.5       Weight     11,283     2.3       Overweight     11,283     2.3       Obese or morbidly obese     114,326     22.8       Comorbidites (at siagnosis)     Hypertension     288,611     57.6       Atrial fibrillation     35,353     7.1     Other arrhythmia     58,889     11.8       Myocardial infarction     17,091     3.4     Cerebrovascular disease     34,200     6.8       Diabetes mellitus: uncomplicated     112,531     22.5     10     134     22.5       Diabetes mellitus: complicated     45,328     9.1     6.6     2.5     9.1     2.0     6.8       Diabetes mellitus: complicated     112,531     22.5     9.1     6.6     2.3     9.1     6.6     2.8     9.1     7.1     9.0     8.61     0.2     9.0     8.61     0.2 <td>&gt;100,000</td> <td>156,226</td> <td>31.2</td>	>100,000	156,226	31.2
EducationHigh school diploma or less136,06527.2Some college or associate degree282,16556.3Bachelor degree or higher82,56216.5Weight11,2832.3Overweight11,2832.3Obese or morbidly obese114,32622.8Comorbidites (at siagnosis)114,32622.8Hypertension288,61157.6Atrial fibrillation35,3537.1Other arrhythmia58,88911.8Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Unknown	82,472	16.5
High school diploma or less     136,065     27.2       Some college or associate degree     282,165     56.3       Bachelor degree or higher     82,562     16.5       Weight     11,283     2.3       Overweight     11,283     2.3       Obese or morbidly obese     114,326     22.8       Comorbidites (at siagnosis)     114,326     22.8       Hypertension     288,611     57.6       Atrial fibrillation     35,353     7.1       Other arrhythmia     58,889     11.8       Myocardial infarction     17,091     3.4       Cerebrovascular disease     34,200     6.8       Diabetes mellitus: uncomplicated     112,531     22.5       Diabetes mellitus: complicated     45,328     9.1       Congestive heart failure     35,401     7.1       Peripheral vascular disease     32,819     6.6       Dementia     861     0.2       Pulmonary disease     95,239     19.0       Rheumatic disease     23,241     4.6       Plegia/paresis     3104     0.6	Education		
Some college or associate degree     282,165     56.3       Bachelor degree or higher     82,562     16.5       Weight     375,183     74.9       Normal     375,183     74.9       Overweight     11,283     2.3       Obese or morbidly obese     114,326     22.8       Comorbidites (at siagnosis)     114,326     22.8       Hypertension     288,611     57.6       Atrial fibrillation     35,353     7.1       Other arrhythmia     58,889     11.8       Myocardial infarction     17,091     3.4       Cerebrovascular disease     34,200     6.8       Diabetes mellitus: uncomplicated     112,531     22.5       Diabetes mellitus: complicated     45,328     9.1       Congestive heart failure     35,401     7.1       Peripheral vascular disease     32,819     6.6       Dementia     861     0.2       Pulmonary disease     95,239     19.0       Rheumatic disease     23,241     4.6       Plegia/paresis     3104     0.6	High school diploma or less	136,065	27.2
Bachelor degree or higher82,56216.5WeightNormal375,18374.9Overweight11,2832.3Obese or morbidly obese114,32622.8Comorbidites (at siagnosis)Hypertension288,61157.6Atrial fibrillation35,3537.1Other arrhythmia58,88911.8Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease13,0282.6Peptic ulcer disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Some college or associate degree	282,165	56.3
Weight375,18374.9Normal375,18374.9Overweight11,2832.3Obese or morbidly obese114,32622.8Comorbidites (at siagnosis)114,32622.8Hypertension288,61157.6Atrial fibrillation35,3537.1Other arrhythmia58,88911.8Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease13,0282.6Peptic ulcer disease13,0282.6Peptic ulcer disease31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Bachelor degree or higher	82,562	16.5
Normal375,18374.9Overweight11,2832.3Obese or morbidly obese114,32622.8Comorbidites (at siagnosis)114,32622.8Hypertension288,61157.6Atrial fibrillation35,3537.1Other arrhythmia58,88911.8Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Weight		
Overweight11,2832.3Obese or morbidly obese114,32622.8Comorbidites (at siagnosis)114,32622.8Hypertension288,61157.6Atrial fibrillation35,3537.1Other arrhythmia58,88911.8Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease13,0282.6Peptic ulcer disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Normal	375,183	74.9
Obese or morbidly obese114,32622.8Comorbidites (at siagnosis)14,32622.8Hypertension288,61157.6Atrial fibrillation35,3537.1Other arrhythmia58,88911.8Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Overweight	11,283	2.3
Comorbidites (at siagnosis)Hypertension288,611Atrial fibrillation35,353Other arrhythmia58,889Myocardial infarction17,0913.4Cerebrovascular diseaseDiabetes mellitus: uncomplicated112,531Diabetes mellitus: complicated45,328Diabetes mellitus: complicated45,328Peripheral vascular disease32,8196.6DementiaPulmonary disease95,23919.0Rheumatic disease13.0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,865Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Obese or morbidly obese	114.326	22.8
Hypertension288,61157.6Atrial fibrillation35,3537.1Other arrhythmia58,88911.8Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Comorbidites (at siagnosis)	,	
Atrial fibrillation35,3537.1Other arrhythmia58,88911.8Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Hypertension	288.611	57.6
Other arrhythmia58,88911.8Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Atrial fibrillation	35,353	7.1
Myocardial infarction17,0913.4Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Other arrhythmia	58,889	11.8
Cerebrovascular disease34,2006.8Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease44180.9Liver disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Myocardial infarction	17.091	3.4
Diabetes mellitus: uncomplicated112,53122.5Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	, Cerebrovascular disease	34.200	6.8
Diabetes mellitus: complicated45,3289.1Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Diabetes mellitus: uncomplicated	112.531	22.5
Congestive heart failure35,4017.1Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease44180.9Liver disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Diabetes mellitus: complicated	45.328	9.1
Peripheral vascular disease32,8196.6Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease44180.9Liver disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Congestive heart failure	35.401	7.1
Dementia8610.2Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease44180.9Liver disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Peripheral vascular disease	32.819	6.6
Pulmonary disease95,23919.0Rheumatic disease13,0282.6Peptic ulcer disease44180.9Liver disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Dementia	861	0.2
Rheumatic disease13,0282.6Peptic ulcer disease44180.9Liver disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Pulmonary disease	95,239	19.0
Peptic ulcer disease44180.9Liver disease23,2414.6Plegia/paresis31040.6Renal disease28,8655.8Malignancy nonskin26,2925.3Metastatic tumor24230.5AIDS/HIV14,1252.8	Rheumatic disease	13.028	2.6
Liver disease     23,241     4.6       Plegia/paresis     3104     0.6       Renal disease     28,865     5.8       Malignancy nonskin     26,292     5.3       Metastatic tumor     2423     0.5       AIDS/HIV     14,125     2.8	Peptic ulcer disease	4418	0.9
Plegia/paresis     3104     0.6       Renal disease     28,865     5.8       Malignancy nonskin     26,292     5.3       Metastatic tumor     2423     0.5       AIDS/HIV     14,125     2.8	Liver disease	23.241	4.6
Renal disease     28,865     5.8       Malignancy nonskin     26,292     5.3       Metastatic tumor     2423     0.5       AIDS/HIV     14,125     2.8	Plegia/paresis	3104	0.6
Malignancy nonskin     26,292     5.3       Metastatic tumor     2423     0.5       AIDS/HIV     14,125     2.8	Renal disease	28.865	5.8
Metastatic tumor     2423     0.5       AIDS/HIV     14,125     2.8	Malignancy nonskin	26,292	5.3
AIDS/HIV 14,125 2.8	Metastatic tumor	2423	0.5
	AIDS/HIV	14,125	2.8

<sup>a</sup>Demographic data for 500,792 patients with obstructive sleep apnea from Optum's deidentified Clinformatics Data Mart database. <sup>b</sup>Mean (SD).

were continuously available in our database, with a minimum interval of 1 year. All demographic and medical comorbidities were combined in the same analysis.

All analyses were conducted on all variables at the same time (*survival* package, R version 4.0.0; R Project for Statistical Computing). Statistical significance was met below a 2-tailed P value of .05.

# Results

Our analysis comprised 500,792 insured patients with a diagnosis of OSA based on our inclusion criteria. All variables in our multivariate analysis are presented in **Tables 2** and **3**. We included patient data from 2004 to 2018. The age range was 18 to 90 years at diagnosis, with a median of 54. Median follow-up postdiagnosis was 872 days. As reported by the database, this population had a racial/ethic breakdown of White (391,506), Asian (12,140), Black (50,393), and Hispanic (46,753). Our multivariable Cox regression included all demographic and medical covariates.

Among demographic variables, increased age above the 18- to 29-year range (P < .001) and Black race (P = .020) were independently associated with decreased likelihood for receiving surgery for sleep apnea. Asian race was associated with increased likelihood of receiving surgery for sleep apnea (P = .027). Neither annual income nor education level was significantly associated with surgery for OSA, although yearly income <\$50,000 trended toward an association with a lower likelihood for receiving surgical treatment (P = .064; **Table 2**).

Among prior comorbidities—which, for the purpose of our analysis, were necessarily present at the time of OSA diagnosis—obesity (P < .001) and congestive heart failure (P < .001) were independently associated with decreased likelihood for receiving surgery for sleep apnea. Pulmonary disease (P < .001) and liver disease (P < .01) were associated with increased likelihood of receiving surgery for sleep apnea. No association was found between surgical treatment for OSA and those who are overweight or those diagnosed with diseases associated with OSA, such as dementia and pulmonary disease (**Table 3**).

Among comorbidities analyzed in a time-varying analysis, which accounted for new diagnosis of a disease between the time of OSA diagnosis and the endpoint, diabetes associated with chronic complications (P = .022) and atrial fibrillation (P < .01) were associated with decreased likelihood of surgery for sleep apnea. Hypertension (P < .01) and other arrythmias (P < .001) were associated with increased likelihood of surgery for sleep apnea. Neither diagnosis of uncomplicated diabetes nor having a heart attack or stroke during the follow-up period was associated with subsequent surgery to treat OSA (**Table 3**).

# Limitations

Our data were derived from a large database of insured patients, which introduces several limitations. All demographic and health information was extrapolated from insurance codes. Furthermore, the study population includes only insured persons, which limits its applicability to the general population. However, as Black Americans are at higher risk of being uninsured than their White counterparts and as uninsured people have reduced access to health care, our findings likely underestimate any disparity in care.

# Discussion

Our analysis reveals insight into the management of OSA and the population of patients who receive surgical treatment. Our

Table 2. Demographic Variables.<sup>a</sup>

Variable (reference)	Hazard ratio	95% CI	P value
Age at diagnosis, y (18-29 y)			
30-39	0.566006	0.48099-0.666	7.18E-12 <sup>b</sup>
40-49	0.394572	0.33648-0.4627	<2e-16 <sup>b</sup>
50-59	0.295984	0.25077-0.3494	<2e-16 <sup>b</sup>
60-69	0.164186	0.13551-0.1989	<2e-16 <sup>b</sup>
70-79	0.084367	0.06549-0.1087	<2e-16 <sup>b</sup>
≥ <b>80</b>	0.056831	0.02985-0.1082	<2e-16 <sup>b</sup>
Race/ethnicity (White)			
Asian	1.286962	1.02849-1.6104	.027418 <sup>c</sup>
Black	0.858251	0.7542-0.9767	.020439 <sup>c</sup>
Hispanic	0.988592	0.87486-1.1171	.854022
Annual income, \$ (>100,000)			
<50,000	0.896209	0.79824-1.0062	.063555
50,000-100,000	0.937798	0.8525-1.0316	.186847
Unknown	1.194491	1.06762-1.3364	.001922
Education (bachelor degree or higher)			
High school diploma or less	0.912073	0.80446-1.0341	.150802
Some college degree	0.939278	0.8474-1.0411	.23297
No. of children in household	1.03334	0.98432-1.0848	.18596

Abbreviation: OSA, obstructive sleep apnea.

<sup>a</sup>Multivariate logistic regression of the impact of demographic variables on receiving surgery for OSA. Among patients with OSA, Black race (vs a reference race of White) and increasing age (vs a reference age of 18-29 years) were associated with a decreased rate of OSA surgery. Asian race was associated with an increased rate of OSA surgery.

<sup>b</sup>P < .001.

<sup>c</sup>P < .05.

data do not shed light on CPAP adherence for which there are known disparities.<sup>13</sup> Surgery was avoided in patients with medical comorbidities that might increase the risk of general anesthesia, such as heart disease, obesity, and diabetes with chronic complications. In contrast, hypertension, pulmonary disease, and arrythmias (with the exception of atrial fibrillation) were associated with increased rates of surgery. Considering that treating OSA with CPAP is known to reduce blood pressure<sup>37</sup> and recurrence of arrythmias,<sup>33</sup> our results suggest that surgery for sleep apnea may be performed in the interest of optimizing health and reducing cardiovascular and pulmonary risk factors. The association seen in several other variables is more difficult to explain. The reduced incidence of surgery in patients with atrial fibrillation may be related to hesitance to stop the anticoagulation that may be prescribed, or it may be confounded by inconsistencies with coding (if coded as other arrythmia). Indeed, the main limitation of our analysis lies in the sourcing of data through insurance codes.

Asian race corresponded to an increased likelihood of surgical treatment of OSA. This may be explained by lower rates of obesity in Asian communities as compared with Caucasian communities. While obesity is a risk factor for OSA among all ethnicities, including Asian, surgical treatment may be more commonly offered in those with lower body mass index.<sup>39</sup> For example, Lam et al found that Asian individuals had more severe OSA, partly due to a more crowded posterior oropharynx,<sup>40</sup> suggesting that Asian patients with OSA may be more amenable to surgical intervention. There are limited data on the role of access to health care among Asian Americans.

The finding on which we are choosing to focus our discussion is that Black race is a risk factor for failure to receive surgical treatment of OSA, independent of all other demographic variables and comorbidities. In other words, insured Black individuals are less likely to receive surgery for sleep apnea than their White counterparts, independent of income, wealth, and comorbid health conditions. These findings raise the question of why.

One historical explanation pertains to craniofacial anatomy, in which there are known racial and ethnic variabilities, some of which have greater association with OSA.<sup>6,41</sup> Whereas White individuals with OSA have differences in bony and soft tissue cephalometric measures as compared with White controls, differences in bony structures do not predispose to OSA in Black individuals.

In contrast, increased tongue area and increased soft palate length are associated with increased risk of OSA in Black individuals.<sup>41</sup> This may explain some of the disparities in rates of maxillofacial surgery. However, these surgical procedures are relatively rare and are typically performed after failure of less invasive surgery for OSA; moreover, maxillofacial surgery was excluded from our analysis.

#### Table 3. Comorbid Variables.<sup>a</sup>

	Hazard ratio	95% CI	P value
Time-varying conditions			
Hypertension	1.167635	1.0516 to 1.2965	.003706 <sup>b</sup>
Atrial fibrillation	0.614105	0.45198 to 0.8344	.001822 <sup>b</sup>
Other arrhythmia	1.396211	1.20382 to 1.6193	1.02E-05 <sup>c</sup>
Myocardial infarction	1.147804	0.85349 to 1.5436	.361793
Cerebrovascular disease	1.136432	0.91483 to 1.4117	.247828
Diabetes mellitus: uncomplicated	0.893512	0.75673 to 1.055	.184104
Diabetes mellitus: complicated	0.744218	0.57789 to 0.9584	.022076 <sup>d</sup>
Prior comorbidities			
Overweight <sup>e</sup>	1.2281	0.92003 to 1.6393	.16322
Obese <sup>e</sup>	0.692717	0.92003 to 0.8034	1.20E-06 <sup>c</sup>
Congestive heart failure	0.655525	0.51088 to 0.8411	.000899°
Peripheral vascular disease	0.992792	0.79238 to 1.2439	.949862
Dementia	0.36392	0.0512 to 2.5865	.312387
Pulmonary disease	1.203652	1.09152 to 1.3273	.000203°
Rheumatic disease	0.618996	0.19425 to 1.9725	.417278
Peptic ulcer disease	0.629782	0.34805 to 1.1395	.12646
Liver disease	1.259623	1.05943 to 1.4976	.008956 <sup>b</sup>
Plegia/paresis	0.738615	0.36875 to 1.4795	.39264
Renal disease	0.850543	0.64936 to 1.114	.239745
Malignancy nonskin	0.994339	0.80655 to 1.2258	.957601
Metastatic tumor	1.01315	0.48207 to 2.1293	.972497
AIDS/HIV	1.805257	0.58122 to 5.6071	.30699

Abbreviation: OSA, obstructive sleep apnea.

<sup>a</sup>Multivariate logistic regression of the impact of health on receiving surgery for OSA. Among patients with OSA, diagnosis of diabetes, atrial fibrillation, obesity, and congestive heart failure were associated with a decreased rate of OSA surgery. Diagnoses of hypertension, other arrhythmias, pulmonary disease, and liver disease were associated with an increased rate of OSA surgery.

<sup>b</sup>P < .01.

<sup>c</sup>P < .001.

<sup>d</sup>P < .05.

<sup>e</sup>Body mass index: overweight, 25-29.9; obese, >30.

We cannot discount mistrust of physicians as a factor explaining our result. The US medical system has a long history of mistreating Black people. Notable examples include forced sterilizations of Black women and the Tuskegee syphilis study, which withheld treatment from hundreds of Black men. As a result, this community has developed significant medical mistrust, which pervades the health care system. A November 2020 study by the Pew Research Center found that 42% of Black individuals intended to receive the COVID-19 vaccine, in contrast to 61% of White individuals (83% of Asian individuals).<sup>42</sup> This intention played out in reality, and as of December 13, 2021, just 51% of Black Americans have received at least 1 COVID-19 vaccine dose, in contrast to 58% of White Americans (77% of Asian Americans).<sup>43</sup> This mistrust developed and persisted because of systemic and overt racism, and it must be addressed rather than dismissed if we wish to decrease disparities in health. Indeed, OSA is emblematic of a much broader trend in public health.

To correct this and move toward a more equitable and healthy society, we must direct our attention and resources toward addressing racial and ethnic health disparities in our approach to future diagnostic and therapeutic interventions for OSA. Clinicians must educate and counsel patients in a tailored manner, sensitive to the justified mistrust as well as to the disparities in health literacy and exposure to the health system. Ultimately, this is a population health issue that is likely best addressed at the level of community outreach and policy. Research has demonstrated that culturally tailored approaches toward education, evaluation, and treatment of OSA, as developed with the input and approval of the targeted communities, can significantly improve outcomes. Specifically engaging community leaders, working through community centers and faith-based organizations, and developing tailored websites may help effectively reach minority populations.<sup>44-46</sup> In 2010, the World Health Organization published a document outlining policy approaches toward achieving gender equality and health equity.<sup>47</sup> We assert that similar policy recommendations should be developed for race and ethnicity. Clinicians, companies, and policy makers must be ready and willing to open their eyes, ears, and minds to the perspectives of the underserved for us to dismantle the systemic barriers and gaps that perpetuate racial and ethnic health disparities in this country.

#### **Author Contributions**

Samuel M. Cohen, conceived of project, assisted with analysis, and wrote manuscript; Javier J.M. Howard, conceived of project, assisted with analysis, and wrote manuscript; Michael C. Jin, Performed data analysis; Jason Qian, assisted with data analysis; Robson Capasso, edited manuscript.

## Disclosures

Competing interests: None.

Sponsorships: None.

Funding source: None.

### References

- Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and racial/ethnic disparities. *JAMA*. Published online June 23, 2020. doi:10.1001/jama.2020.8598
- Anyane-Yeboa A, Sato T, Sakuraba A. Racial disparities in COVID-19 deaths reveal harsh truths about structural inequality in America. *J Intern Med.* Published online June 15, 2020. doi: 10.1111/joim.13117
- Wright J, Johns R, Watt I, Melville A, Sheldon T. Health effects of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure: a systematic review of the research evidence. *BMJ*. 1997;314(7084):851-860. doi:10.1136/bmj.314 .7084.851
- Young T, Finn L. Epidemiological insights into the public health burden of sleep disordered breathing: sex differences in survival among sleep clinic patients. *Thorax*. 1998;53(suppl 3):S16-S19. doi:10.1136/thx.53.2008.s16
- Kripke DF, Ancoli-Israel S, Klauber MR, Wingard DL, Mason WJ, Mullaney DJ. Prevalence of sleep-disordered breathing in ages 40-64 years: a population-based survey. *Sleep*. 1997;20(1): 65-76. doi:10.1093/sleep/20.1.65
- Redline S, Tishler PV, Hans MG, Tosteson TD, Strohl KP, Spry K. Racial differences in sleep-disordered breathing in African-Americans and Caucasians. *Am J Respir Crit Care Med.* 1997; 155(1):186-192. doi:10.1164/ajrccm.155.1.9001310
- Ancoli-Israel S, Klauber MR, Stepnowsky C, Estline E, Chinn A, Fell R. Sleep-disordered breathing in African-American elderly. *Am J Respir Crit Care Med.* 1995;152(6, pt 1):1946-1949. doi:10.1164/ajrccm.152.6.8520760
- Ruiter ME, DeCoster J, Jacobs L, Lichstein KL. Sleep disorders in African Americans and Caucasian Americans: a metaanalysis. *Behav Sleep Med.* 2010;8(4):246-259. doi:10.1080/ 15402002.2010.509251
- Weinstock TG, Rosen CL, Marcus CL, et al. Predictors of obstructive sleep apnea severity in adenotonsillectomy candidates. *Sleep*. 2014;37(2):261-269. doi:10.5665/sleep.3394
- Stepanski E, Zayyad A, Nigro C, Lopata M, Basner R. Sleep-disordered breathing in a predominantly African-American pediatric population. *J Sleep Res.* 1999;8(1):65-70. doi:10.1046/j .1365-2869.1999.00136.x
- Rosen CL, Larkin EK, Kirchner HL, et al. Prevalence and risk factors for sleep-disordered breathing in 8- to 11-year-old children: association with race and prematurity. *J Pediatr.* 2003; 142(4):383-389. doi:10.1067/mpd.2003.28

- Redline S, Tishler PV, Schluchter M, Aylor J, Clark K, Graham G. Risk factors for sleep-disordered breathing in children: associations with obesity, race, and respiratory problems. *Am J Respir Crit Care Med.* 1999;159(5, pt 1):1527-1532. doi:10. 1164/ajrccm.159.5.9809079
- Billings ME, Auckley D, Benca R, et al. Race and residential socioeconomics as predictors of CPAP adherence. *Sleep*. 2011; 34(12):1653-1658. doi:10.5665/sleep.1428
- Balachandran JS, Yu X, Wroblewski K, Mokhlesi B. A brief survey of patients' first impression after CPAP titration predicts future CPAP adherence: a pilot study. *J Clin Sleep Med.* 2013; 9(3):199-205. doi:10.5664/jcsm.2476
- Wallace DM, Shafazand S, Aloia MS, Wohlgemuth WK. The association of age, insomnia, and self-efficacy with continuous positive airway pressure adherence in Black, White, and Hispanic US veterans. *J Clin Sleep Med.* 2013;9(9):885-895. doi:10.5664/jcsm.2988
- Guralnick AS, Pant M, Minhaj M, Sweitzer BJ, Mokhlesi B. CPAP adherence in patients with newly diagnosed obstructive sleep apnea prior to elective surgery. *J Clin Sleep Med.* 2012; 8(5):501-506. doi:10.5664/jcsm.2140
- Means MK, Ulmer CS, Edinger JD. Ethnic differences in continuous positive airway pressure (CPAP) adherence in veterans with and without psychiatric disorders. *Behav Sleep Med.* 2010; 8(4):260-273. doi:10.1080/15402002.2010.509255
- Joo MJ, Herdegen JJ. Sleep apnea in an urban public hospital: assessment of severity and treatment adherence. J Clin Sleep Med. 2007;3(3):285-288.
- Quintos A, Naranjo M, Kelly C, Quan SF, Sharma S. Recognition and treatment of sleep-disordered breathing in obese African American hospitalized patients may improve outcome. *J Natl Med Assoc*. 2019;111(2):176-184. doi:10.1016/j .jnma.2018.09.003
- Boss EF, Smith DF, Ishman SL. Racial/ethnic and socioeconomic disparities in the diagnosis and treatment of sleepdisordered breathing in children. *Int J Pediatr Otorhinolaryngol.* 2011;75(3):299-307. doi:10.1016/j.ijporl.2010.11.006
- Johnson DA, Guo N, Rueschman M, Wang R, Wilson JG, Redline S. Prevalence and correlates of obstructive sleep apnea among African Americans: the Jackson Heart Sleep Study. *Sleep*. 2018;41(10):zsy154. doi:10.1093/sleep/zsy154
- Jean-Louis G, von Gizycki H, Zizi F, Dharawat A, Lazar JM, Brown CD. Evaluation of sleep apnea in a sample of black patients. *J Clin Sleep Med*. 2008;4(5):421-425.
- Scharf SM, Seiden L, DeMore J, Carter-Pokras O. Racial differences in clinical presentation of patients with sleep-disordered breathing. *Sleep Breath*. 2004;8(4):173-183. doi:10.1007/ s11325-004-0173-5
- Meetze K, Gillespie MB, Lee FS. Obstructive sleep apnea: a comparison of Black and White subjects. *Laryngoscope*. 2002; 112(7, pt 1):1271-1274. doi:10.1097/00005537-200207000-00024
- Shaw R, McKenzie S, Taylor T, et al. Beliefs and attitudes toward obstructive sleep apnea evaluation and treatment among blacks. *J Natl Med Assoc.* 2012;104(11-12):510-519. doi:10 .1016/s0027-9684(15)30217-0
- 26. Nieto FJ, Young TB, Lind BK, et al. Association of sleepdisordered breathing, sleep apnea, and hypertension in a large

community-based study: Sleep Heart Health Study. *JAMA*. 2000;283(14):1829-1836. doi:10.1001/jama.283.14.1829

- Young T, Shahar E, Nieto FJ, et al. Predictors of sleepdisordered breathing in community-dwelling adults: the Sleep Heart Health Study. *Arch Intern Med.* 2002;162(8):893-900. doi:10.1001/archinte.162.8.893
- Dudley KA, Patel SR. Disparities and genetic risk factors in obstructive sleep apnea. *Sleep Med.* 2016;18:96-102. doi:10. 1016/j.sleep.2015.01.015
- Bleich SN, Thorpe RJ, Sharif-Harris H, Fesahazion R, Laveist TA. Social context explains race disparities in obesity among women. *J Epidemiol Community Health*. 2010;64(5):465-469. doi:10.1136/jech.2009.096297
- Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. *J Clin Endocrinol Metab.* 2004; 89(6):2590-2594. doi:10.1210/jc.2004-0339
- Rossen LM. Neighbourhood economic deprivation explains racial/ethnic disparities in overweight and obesity among children and adolescents in the U.S.A. J Epidemiol Community Health. 2014;68(2):123-129. doi:10.1136/jech-2012-202245
- McIsaac DI, Gershon A, Wijeysundera D, Bryson GL, Badner N, van Walraven C. Identifying obstructive sleep apnea in administrative data: a study of diagnostic accuracy. *Anesthesiology*. 2015;123(2):253-263. doi:10.1097/ALN.000000000000692
- 33. Wang X, Yue Z, Liu Z, et al. Continuous positive airway pressure effectively ameliorates arrhythmias in patients with obstructive sleep apnea-hypopnea via counteracting the inflammation. *Am J Otolaryngol.* 2020;41(6):102655. doi:10.1016/j .amjoto.2020.102655
- 34. Garcia-Rio F, Alonso-Fernández A, Armada E, et al. CPAP effect on recurrent episodes in patients with sleep apnea and myocardial infarction. *Int J Cardiol.* 2013;168(2):1328-1335. doi:10.1016/j.ijcard.2012.12.015
- Shukla A, Aizer A, Holmes D, et al. Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis. *JACC Clin Electrophysiol.* 2015;1(1-2):41-51. doi:10.1016/j .jacep.2015.02.014
- 36. Martínez-García MA, Soler-Cataluña JJ, Ejarque-Martínez L, et al. Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study. *Am J Respir Crit Care Med.* 2009;180(1):36-41. doi:10.1164/rccm.200808-1341OC
- Pedrosa RP, Drager LF, de Paula LKG, Amaro ACS, Bortolotto LA, Lorenzi-Filho G. Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial. *Chest.* 2013; 144(5):1487-1494. doi:10.1378/chest.13-0085

- Babu AR, Herdegen J, Fogelfeld L, Shott S, Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. *Arch Intern Med.* 2005;165(4): 447-452. doi:10.1001/archinte.165.4.447
- Hnin K, Mukherjee S, Antic NA, et al. The impact of ethnicity on the prevalence and severity of obstructive sleep apnea. *Sleep Med Rev.* 2018;41:78-86. doi:10.1016/j.smrv.2018.01.003
- Lam B, Ip MS, Tench E, Ryan CF. Craniofacial profile in Asian and White subjects with obstructive sleep apnoea. *Thorax*. 2005; 60(6):504-510. doi:10.1136/thx.2004.031591
- 41. Cakirer B, Hans MG, Graham G, Aylor J, Tishler PV, Redline S. The relationship between craniofacial morphology and obstructive sleep apnea in Whites and in African-Americans. *Am J Respir Crit Care Med.* 2001;163(4):947-950. doi:10.1164/ ajrccm.163.4.2005136
- 42. Pew Research Center. Intent to get a COVID-19 vaccine rises to 60% as confidence in research and development process increases. Published December 3, 2020. https://www.pewre search.org/science/2020/12/03/intent-to-get-a-covid-19-vaccinerises-to-60-as-confidence-in-research-and-development-processincreases/
- 43. Ndugga N, Hill L, Artiga S, Haldar S. Latest data on COVID-19 vaccinations by race/ethnicity. Kaiser Family Foundation. Published December 15, 2021. https://www.kff.org/coronaviruscovid-19/issue-brief/latest-data-on-covid-19-vaccinations-by-ra ce-ethnicity/
- 44. Seixas AA, Trinh-Shevrin C, Ravenell J, Ogedegbe G, Zizi F, Jean-Louis G. Culturally tailored, peer-based sleep health education and social support to increase obstructive sleep apnea assessment and treatment adherence among a community sample of Blacks: study protocol for a randomized controlled trial. *Trials*. 2018;19(1):519. doi:10.1186/s13063-018-2835-9
- 45. Williams NJ, Jean-Louis G, Brown CD, McFarlane SI, Boutin-Foster C, Ogedegbe G. Telephone-delivered behavioral intervention among blacks with sleep apnea and metabolic syndrome: study protocol for a randomized controlled trial. *Trials*. 2014;15: 225. doi:10.1186/1745-6215-15-225
- Robbins R, Senathirajah Y, Williams NJ, et al. Developing a tailored website for promoting awareness about obstructive sleep apnea (OSA) among Blacks in community-based settings. *Health Commun.* 2019;34(5):567-575. doi:10.1080/10410236 .2018.1423865
- World Health Organization. Policy approaches to engaging men and boys in achieving gender equality and health equity. Published 2010. https://apps.who.int/iris/handle/10665/44402